Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing

Lewczuk, P., Kornhuber, J., Vanmechelen, E., Peters, O., Heuser, I., Maier, W., Jessen, F., Burger, K., Hampel, H., Frolich, L., Henn, F., Falkai, P., Ruther, E., Jahn, H., Luckhaus, Ch, Perneczky, R., Schmidtke, K., Schroder, J., Kessler, H., Pantel, J., Gertz, H. J., Vanderstichele, H., de Meyer, G., Shapiro, F., Wolf, S., Bibl, M., Wiltfang, J. (June 2010) Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Experimental Neurology, 223 (2). pp. 366-70. ISSN 1090-2430 (Electronic) 1090-2430 (Linking)

DOI: 10.1016/j.expneurol.2009.07.024


We measured concentrations of Abeta peptides 1-42 and 1-40, and their ratio in plasma of patients carefully categorized clinically and neurochemically as having AD or other dementias with a newly commercially available multiplexing assay, characterized by reasonable laboratory performance (intra-assay imprecision in the range of 1.3-3.8% for Abeta1-42, and 1.8-4.1% for Abeta1-40, inter-assay imprecision for Abeta1-42, Abeta1-40, and Abeta1-42/Abeta1-40 concentration ratio in the range of 2.3-11.5%, 2.2-10.4% and 4.2-9.7%, respectively). Patients with AD or mild cognitive impairment of AD type (MCI-AD) whose clinical diagnosis was supported with CSF biomarkers (n=193) had significantly lower Abeta1-42 plasma concentrations (p<0.007), and Abeta1-42/1-40 ratios (p<0.003) compared to patients with other dementias and MCI of other types (n=64). No significant differences between persons with MCI of AD type and patients with early AD were observed, or between MCI of other types versus patients with early dementia of other types. Our findings reconfirm the hypothesis that alterations of biomarker concentrations occur early in a preclinical AD stage and that these alterations are also reflected in plasma.

Item Type: Paper
Uncontrolled Keywords: Aged Aged, 80 and over Alzheimer Disease/blood/cerebrospinal fluid/*diagnosis Amyloid beta-Peptides/*blood/cerebrospinal fluid Biological Markers/*blood/cerebrospinal fluid Dementia/blood/cerebrospinal fluid/diagnosis Early Diagnosis Enzyme-Linked Immunosorbent Assay Female Humans Immunoassay/*methods Male Middle Aged Peptide Fragments/*blood/cerebrospinal fluid Predictive Value of Tests
Subjects: diseases & disorders > mental disorders > delirium dementia cognitive disorders > Alzheimer's disease
CSHL Authors:
Communities: CSHL labs > Henn lab
Depositing User: Matt Covey
Date: June 2010
Date Deposited: 06 Jun 2014 16:22
Last Modified: 06 Jun 2014 16:22
Related URLs:

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving